secwatch.observer — SEC 8-K summary
======================================

Issuer:     Travere Therapeutics, Inc. (TVTX)
CIK:        0001438533
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0001438533-25-000032
Event type: regulatory
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA accepts Travere's sNDA for FILSPARI in FSGS; PDUFA Jan 13, 2026
-------------------------------------------------------------------

- FDA accepted sNDA for traditional approval of FILSPARI (sparsentan) to treat focal segmental glomerulosclerosis (FSGS).
- PDUFA target action date is January 13, 2026; FDA plans an advisory committee meeting.
- If approved, FILSPARI would be first FDA-approved drug for FSGS, affecting over 40,000 U.S. patients.
- sNDA supported by Phase 3 DUPLEX (met interim proteinuria endpoint, missed primary eGFR slope) and Phase 2 DUET studies.
- No approved pharmacologic treatment currently exists for FSGS.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438533/000143853325000032/0001438533-25-000032-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438533/000143853325000032/tvtx-20250515.htm
  HTML page:      https://secwatch.observer/filing/0001438533-25-000032

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer